J Korean Soc Transplant.  2013 Jun;27(2):42-48.

Pathologic Updates on Antibody Mediated Rejection in Renal Transplantation

• Choi YJ

Abstract

Progress in the field of antibody mediated rejection (ABMR) in kidney transplantation has shown a rapid increase during the past two decades. New pathologic entities have emerged and replace old concepts and diagnostic terms. According to newly acknowledged facts discovered by clinicians, researchers, and pathologists all over the world, an updated classification, rather than Banff 07, is needed. In order to improve the diagnostic accuracy for ABMR in clinicians as well as pathologists, recognition and awareness of various conditions such as C4d-negative ABMR, subclinical ABMR, de novo donor specific antibody, microcirculation inflammation, isolated vascular lesion, antibody-mediated transplant arteriopathy, etc. are essentially important.

Keyword

Antibodies; Graft rejection; Complement C4d; Transplantation; Kidney

MeSH Terms

Antibodies
Complement C4b
Graft Rejection
Humans
Inflammation
Kidney
Kidney Transplantation
Microcirculation
Peptide Fragments
Rejection (Psychology)
Tissue Donors
Transplants
Antibodies
Complement C4b
Peptide Fragments

Reference

1). Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant. 2010; 10:464–71.

2). Solez K, Racusen LC. The Banff classification revisited. Kidney Int. 2013; 83:201–6.

3). Feucht HE, Felber E, Gokel MJ, Hillebrand G, Nattermann U, Brockmeyer C, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol. 1991; 86:464–70.

4). Feucht HE, Mihatsch MJ. Diagnostic value of C4d in renal biopsies. Curr Opin Nephrol Hypertens. 2005; 14:592–8.

5). Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant. 2003; 3:708–14.

6). Nickeleit V, Zeiler M, Gudat F, Thiel G, Mihatsch MJ. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol. 2002; 13:242–51.

7). Cohen D, Colvin RB, Daha MR, Drachenberg CB, Haas M, Nickeleit V, et al. Pros and cons for C4d as a biomarker. Kidney Int. 2012; 81:628–39.

8). Cornell LD. Renal allograft pathology in the sensitized patient. Curr Opin Organ Transplant. 2013; 18:327–36.

9). Mauiyyedi S, Pelle PD, Saidman S, Collins AB, Pascual M, Tolkoff-Rubin NE, et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol. 2001; 12:574–82.

10). Husain S, Sis B. Advances in the Understanding of Transplant Glomerulopathy. Am J Kidney Dis [in press 2013 Jan 23].

11). Fotheringham J, Angel CA, McKane W. Transplant glomerulopathy: morphology, associations and mechanism. Nephron Clin Pract. 2009; 113:c1–7. discussion c.

12). Mengel M, Sis B, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant. 2012; 12:563–70.

13). Mehra NK, Siddiqui J, Baranwal A, Goswami S, Kaur G. Clinical relevance of antibody development in renal transplantation. Ann N Y Acad Sci. 2013; 1283:30–42.

14). Collins AB, Schneeberger EE, Pascual MA, Saidman SL, Williams WW, Tolkoff-Rubin N, et al. Complement acti-vation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol. 1999; 10:2208–14.

15). Loupy A, Hill GS, Suberbielle C, Charron D, Anglicheau D, Zuber J, et al. Significance of C4d Banff scores in ear-ly protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant. 2011; 11:56–65.

16). Sis B, Jhangri GS, Riopel J, Chang J, de Freitas DG, Hidalgo L, et al. A new diagnostic algorithm for anti-body-mediated microcirculation inflammation in kidney transplants. Am J Transplant. 2012; 12:1168–79.

17). Haas M. Pathology of C4d-negative antibody-mediated rejection in renal allografts. Curr Opin Organ Transplant. 2013; 18:319–26.

18). Solez K, Axelsen RA, Benediktsson H, Burdick JF, Cohen AH, Colvin RB, et al. International stand-ardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int. 1993; 44:411–22.

19). Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999; 55:713–23.

20). Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008; 8:753–60.

21). Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation. 1990; 49:85–91.

22). Halloran PF, Schlaut J, Solez K, Srinivasa NS. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation. 1992; 53:550–5.

23). Papadimitriou JC, Drachenberg CB, Munivenkatappa R, Ramos E, Nogueira J, Sailey C, et al. Glomerular inflammation in renal allografts biopsies after the first year: cell types and relationship with antibody-mediated rejection and graft outcome. Transplantation. 2010; 90:1478–85.

24). Khan MA, Nicolls MR. Complement-mediated micro-vascular injury leads to chronic rejection. Adv Exp Med Biol. 2013; 735:233–46.

25). Mauiyyedi S, Crespo M, Collins AB, Schneeberger EE, Pascual MA, Saidman SL, et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopa-thology, and pathologic classification. J Am Soc Nephrol. 2002; 13:779–87.

26). Haas M. Pathologic features of antibody-mediated rejection in renal allografts: an expanding spectrum. Curr Opin Nephrol Hypertens. 2012; 21:264–71.

27). Lefaucheur C, Loupy A, Vernerey D, Duong-Van-Huyen JP, Suberbielle C, Anglicheau D, et al. Antibody-mediated vascular rejection of kidney allografts: a population- based study. Lancet. 2013; 381:313–9.

28). Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant. 2007; 7:518–26.

29). Mengel M, Chan S, Climenhaga J, Kushner YB, Regele H, Colvin RB, et al. Banff Initiative for Quality Assurance in Transplantation (BIFQUIT): reproduci-bility of C4d immunohistochemistry in kidney allografts. Am J Transplant. 2013; 13:1235–45.

30). Sarma JV, Ward PA. The complement system. Cell Tissue Res. 2011; 343:227–35.

31). Stegall MD, Chedid MF, Cornell LD. The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol. 2012; 8:670–8.

32). Haas M. The significance of C4d staining with minimal histologic abnormalities. Curr Opin Organ Transplant. 2010; 15:21–7.

33). Takeda A, Otsuka Y, Horike K, Inaguma D, Hiramitsu T, Yamamoto T, et al. Significance of C4d deposition in antibody-mediated rejection. Clin Transplant. 2012; 26(Suppl 24):43–8.

34). de Kort H, Willicombe M, Brookes P, Dominy KM, Santos-Nunez E, Galliford JW, et al. Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. Am J Transplant. 2013; 13:485–92.

35). Sis B, Campbell PM, Mueller T, Hunter C, Cockfield SM, Cruz J, et al. Transplant glomerulopathy, late anti-body-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant. 2007; 7:1743–52.

36). Lim BJ, Joo DJ, Kim YS, Jeong HJ. Accompanying renal injuries did not impact graft survival in patients with transplant glomerulopathy. Transplant Proc. 2012; 44:616–8.

37). Haas M, Mirocha J. Early ultrastructural changes in renal allografts: correlation with antibody-mediated rejection and transplant glomerulopathy. Am J Transplant. 2011; 11:2123–31.

38). Boonyapredee M, Moore J. Electron microscopy in de-termining the etiology of kidney allograft dysfunction. Transplant Proc. 2012; 44:2992–6.

39). Liapis G, Singh HK, Derebail VK, Gasim AM, Kozlowski T, Nickeleit V. Diagnostic significance of peritubular ca-pillary basement membrane multilaminations in kidney allografts: old concepts revisited. Transplantation. 2012; 94:620–9.

40). Hill GS, Nochy D, Loupy A. Accelerated arteriosclerosis: a form of transplant arteriopathy. Curr Opin Organ Transplant. 2010; 15:11–5.

41). Lerut E, Naesens M, Kuypers DR, Vanrenterghem Y, Van Damme B. Subclinical peritubular capillaritis at 3 months is associated with chronic rejection at 1 year. Transplantation. 2007; 83:1416–22.

42). Sis B. Endothelial molecules decipher the mechanisms and functional pathways in antibody-mediated rejection. Hum Immunol. 2012; 73:1218–25.

43). Hidalgo LG, Sis B, Sellares J, Campbell PM, Mengel M, Einecke G, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant. 2010; 10:1812–22.